Cargando…

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art

Detalles Bibliográficos
Autores principales:	Hermouet, Sylvie, Hasselbalch, Hans C., Čokić, Vladan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670867/ https://www.ncbi.nlm.nih.gov/pubmed/26681841 http://dx.doi.org/10.1155/2015/964613

Ejemplares similares

Mutations, inflammation and phenotype of myeloproliferative neoplasms
por: Hermouet, Sylvie
Publicado: (2023)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation
por: Marković, Dragana, et al.
Publicado: (2022)

VEGF Regulation of Angiogenic Factors via Inflammatory Signaling in Myeloproliferative Neoplasms
por: Subotički, Tijana, et al.
Publicado: (2021)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hasselbalch, Hans C., et al.
Publicado: (2021)

The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?
por: Boissinot, Marjorie, et al.
Publicado: (2014)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

Myeloproliferative neoplasms in five multiple sclerosis patients()
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2013)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway
por: Čokić, Vladan P., et al.
Publicado: (2015)

Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms
por: Vukotić, Milica, et al.
Publicado: (2022)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2022)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms – Impact Of Comorbidity
por: Frederiksen, Henrik, et al.
Publicado: (2019)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review
por: Leiva, Orly, et al.
Publicado: (2022)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Targeting Rho Associated Kinases in Leukemia and Myeloproliferative Neoplasms
por: Mali, Raghuveer Singh, et al.
Publicado: (2012)

Crossing the Borders: An Integrated Approach to Myeloproliferative Neoplasms and Mastocytoses
por: Pizzi, Marco
Publicado: (2021)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
por: Koschmieder, Steffen, et al.
Publicado: (2018)

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
por: Christensen, Sarah F., et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms
por: Bjørn, Mads Emil, et al.
Publicado: (2015)

Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons
por: Leiva, Orly, et al.
Publicado: (2023)

Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm
por: Fleischman, Angela G.
Publicado: (2015)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
por: Pedersen, Kasper M., et al.
Publicado: (2018)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tt2m38120i9vr4j4tlcon4m4ee